Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.60 |
| ▸ | LCK | P06239 | 3/20 | 0.37 |
| ▸ | SRC | P12931 | 3/20 | 0.37 |
| ▸ | KDR | P35968 | 3/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4608337 | 1.00 | MAPK14 (0.60) | MAPK14LCKSRCKDRGSK3B | |
| SCHEMBL4609170 | 0.93 | MAPK14 (0.59) | MAPK14 | |
| SCHEMBL4609168 | 0.93 | MAPK14 (0.59) | MAPK14 | |
| SCHEMBL4609124 | 0.92 | MAPK14 (0.58) | MAPK14LCKSRCKDR | |
| SCHEMBL4609120 | 0.92 | MAPK14 (0.58) | MAPK14LCKSRCKDR | |
| SCHEMBL4609953 | 0.91 | MAPK14 (0.59) | MAPK14LCKSRCKDR | |
| SCHEMBL4609947 | 0.91 | MAPK14 (0.59) | MAPK14LCKSRCKDR | |
| SCHEMBL4608978 | 0.91 | MAPK14 (0.59) | MAPK14LCKSRCKDR | |
| SCHEMBL4608972 | 0.91 | MAPK14 (0.59) | MAPK14LCKSRCKDR | |
| SCHEMBL4608445 | 0.91 | MAPK14 (0.61) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449474-B2 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2008-11-11 | — | — | US | claimed |
| EP-1747204-B1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | PROCTER & GAMBLE (US) | 2008-07-30 | — | — | EP | claimed |
| US-20050239811-A1 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-10-27 | — | — | US | claimed |
| US-7449474-B2 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1747204-B1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | PROCTER & GAMBLE (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1377564-B1 | TRANSITION-METAL-CATALYZED PROCESS FOR THE PREPARATION OF STERICALLY HINDERED N-SUBSTITUTED ALKOXYAMINES | CIBA HOLDING INC (CH) | 2008-07-30 | — | — | EP | disclosed |
| EP-1747204-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | The Procter and Gamble Company (US) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005105758-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050239811-A1 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
| EP-1377564-A2 | TRANSITION-METAL-CATALYZED PROCESS FOR THE PREPARATION OF STERICALLY HINDERED N-SUBSTITUTED ALKOXYAMINES | Ciba SC Holding AG (CH) | 2004-01-07 | — | — | EP | disclosed |
| US-6547841-B2 | Reacting sterically hindered nitroxyl compound with diazonium salt of aromatic amine compound in presence of transition metal catalyst | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-04-15 | — | — | US | disclosed |
| US-20030000129-A1 | Transition-metal-catalyzed process for the preparation of sterically hindered N-substituted alkoxy amines | CIBA SPECIALTY CHEMICALS CORP. | 2003-01-02 | — | — | US | disclosed |
| WO-2002079182-A2 | TRANSITION-METAL-CATALYZED PROCESS FOR THE PREPARATION OF STERICALLY HINDERED N-SUBSTITUTED ALKOXYAMINES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030000129-A1 | Transition-metal-catalyzed process for the preparation of sterically hindered N-substituted alkoxy amines | SOD1, NNMT, TYR | MAPK14 3198/4885LCK 1895/4885SRC 2085/4885 |
| US-20050239811-A1 | Tri-substituted ureas as cytokine inhibitors | IL1B, IL1A, IL6 | MAPK14 2674/4885LCK 1578/4885SRC 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.